Силевимиг

Rec. INN (наименование, зарегистрированное ВОЗ)

2618667-99-3

immunoglobulin (G1_L-kappa)_scFv-G1(h-CH2-CH3), anti-[rabies lyssavirus (rabies virus, RABV) glycoprotein G epitope III] and anti-[rabies lyssavirus (rabies virus, RABV) glycoprotein G epitope I] Homo sapiens monoclonal antibody, bispecific;
gamma1 heavy chain Homo sapiens, anti-RABV glycoprotein G epitope III (1-448) [VH (Homo sapiens IGHV3-30*18 (95.9%) -(IGHD) -IGHJ4*01 (92,9%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v32 CH3 W22 (knob), G1v74 CH3 C10 (CH1 (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359), T22>W (367), S10>C (355), D84.4>G (402), G85.4>D (403) (342-446), CHS (447-448)) (119-448)], (221-214')-disulfide with kappa light chain Homo sapiens, anti-RABV glycoprotein G epitope III (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (88.4%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')];
scFv-G1(h-CH2-CH3) heavy chain Homo sapiens, anti-RABV glycoprotein G epitope I (1''-488'') [VH (Homo sapiens IGHV1-69*01 (91.8%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [8.8.20] (26''-33''.51''-58''.97''-116'')) (1''-127'') -15-mer tris(tetraglycyl-seryl) linker (128''-142'') -VL (Homo sapiens IGLV2-11*01 (93.9%) -IGLJ2*01 (100%), CDR-IMGT [9.3.12] (168''-176''.194''-196''.233''-244'')) (143''-256'') -Homo sapiens IGHG1*03 h-CH2-CH3, nG1m1 CH3 E12, M14, G1v37 hinge S5, G1v33 CH3 S22, A24, V86 (hole), G1v75 CH3 C5 (hinge 1-15 C5>S (261'') (257''-271''), CH2 (272''-381''), CH3 T22>S (407''), L24>A (409''), Y86>V (448''), Y5>C (390'') (382''-486''), CHS (487''-488'')) (257''-488'')]; dimer (227-267'':230-270'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-S, glycoform alfa

Поделиться этой страницей